Michael A. Foley
Amministratore Delegato presso Deerfield Management LP
Profilo
Michael A.
Foley was the founder of FORMA Therapeutics, Inc. (founded in 2008) where he held the title of Director until 2020, and Forma Therapeutics Holdings, Inc. (founded in 2011) where he held the title of Independent Non-Executive Director.
Dr. Foley's current job(s) include Chief Executive Officer at Deerfield Management LP (since 2018) and Director at Quentis Therapeutics, Inc. Dr. Foley's former job(s) include Chief Executive Officer & Sanders Director at Tri-Institutional Therapeutics Discovery Institute, Inc. (2013-2018), Director-Medicinal Chemistry at The Broad Institute, Inc., Principal at Harvard University, Vice President-Chemistry at Infinity Pharmaceuticals, Inc., Principal at Cell Biology & Physiology, and Vice President-Translational Drug Development at Deerfield Discovery & Development LLC.
Dr. Foley's education history includes a doctorate from Harvard University, an undergraduate degree from St. Norbert College, Inc., and a graduate degree from Utah State University.
Dr. Foley is also the founder of CombinatoRx, Inc...
Posizioni attive di Michael A. Foley
| Società | Posizione | Inizio |
|---|---|---|
Quentis Therapeutics, Inc.
 Quentis Therapeutics, Inc. BiotechnologyHealth Technology Quentis Therapeutics, Inc. operates as a biotechnology company. It develops therapeutics in the onco-immunology field. The company was founded by Juan R. cubillos-Ruiz and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
Deerfield Management LP
 Deerfield Management LP Investment ManagersFinance Part of Flynn Management LLC, Deerfield Management LP is a company that provides investment advice. The company is based in New York, NY. Michael A. Foley has been the CEO of the company since 2018. | Amministratore Delegato | 01/05/2018 |
Precedenti posizioni note di Michael A. Foley
| Società | Posizione | Fine |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | Fondatore | 18/06/2020 |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Fondatore | 01/06/2020 |
Tri-Institutional Therapeutics Discovery Institute, Inc.
 Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Amministratore Delegato | 01/04/2018 |
Deerfield Discovery & Development LLC
 Deerfield Discovery & Development LLC Pharmaceuticals: MajorHealth Technology Deerfield Discovery & Development LLC engages in the development of pharmaceutical products. It creates a pipeline of medically important and commercially viable projects at a scale sufficient to produce value for patients and investors. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
| Cell Biology & Physiology | Corporate Officer/Principal | - |
Formazione di Michael A. Foley
| Harvard University | Doctorate Degree |
| St. Norbert College, Inc. | Undergraduate Degree |
| Utah State University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 9 |
|---|---|
Deerfield Management LP
Deerfield Management LP Investment ManagersFinance Part of Flynn Management LLC, Deerfield Management LP is a company that provides investment advice. The company is based in New York, NY. Michael A. Foley has been the CEO of the company since 2018. | Finance |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
| Cell Biology & Physiology | |
Tri-Institutional Therapeutics Discovery Institute, Inc.
Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Commercial Services |
Quentis Therapeutics, Inc.
Quentis Therapeutics, Inc. BiotechnologyHealth Technology Quentis Therapeutics, Inc. operates as a biotechnology company. It develops therapeutics in the onco-immunology field. The company was founded by Juan R. cubillos-Ruiz and is headquartered in New York, NY. | Health Technology |
Deerfield Discovery & Development LLC
Deerfield Discovery & Development LLC Pharmaceuticals: MajorHealth Technology Deerfield Discovery & Development LLC engages in the development of pharmaceutical products. It creates a pipeline of medically important and commercially viable projects at a scale sufficient to produce value for patients and investors. The company is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Michael A. Foley
